Genetic Variants, Treatment Response in B-Cell Lymphoma Investigated

Share this content:
Evidence of inherited genetics contributing to response in patients receiving immunochemotherapy for diffuse large B-cell lymphoma.
Evidence of inherited genetics contributing to response in patients receiving immunochemotherapy for diffuse large B-cell lymphoma.

Evidence is available of inherited genetics contributing to the response achieved in patients receiving immunochemotherapy for diffuse large B-cell lymphoma (DLBCL), according to an article published in the Journal of Clinical Oncology.1

Investigators performed a meta-analysis of four studies, two of which were genome-wide association studies: LNH2003B (N=540), a prospective clinical trial, and the Molecular Epidemiology Resource study (N=312), a prospective observational study.

Independent cohorts of patients from the Specialized Program of Research Excellence (N=391) and Group-Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS)-075 randomized trial (N=294) were genotyped for top single-nucleotide polymorphisms (SNPs).

RELATED: Routine CT Scans for B-cell Lymphoma Patients in Complete Remission Not Recommended

The loci associated with event-free survival (EFS) were rs7712513 at loci 5q23.2 (hazard ratio (HR), 1.39; 95% CI: 1.23-1.57; P=2.08 x 10-7) and rs7765004 at loci 6q21 (HR, 1.38; 95% CI:1.22-1.58; P=7.09 x 10-7); however, genome-wide significance was not met. Investigators also observed that both rs7712513 and rs7765004 (HR, 1.49; 95% CI: 1.27-1.71; P=3.53 x 10-8 vs HR, 1.47; 95% CI: 1.27-1.71; P=5.36 x 10-12) were associated with overall survival.

After an exploratory analysis, a two-SNP risk score, independent of treatment, international prognostic index (IPI), and cell-of-origin classification, was also linked with EFS (P=1.78 x 10-12).

Reference

  1. Ghesquieres H, Slager SL, Jardin R, et al. Genome-wide association study of event-free survival in diffuse large B-cell lymphoma treated with immunochemotherapy [published online ahead of print October 12, 2015]. J Clin Oncol. doi: 10.1200/JCO.2014.60.2573

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters